Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?

Detalles Bibliográficos
Autores principales: Caocci, Giovanni, La Nasa, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220809/
https://www.ncbi.nlm.nih.gov/pubmed/32405693
http://dx.doi.org/10.1007/s00277-020-04067-6
_version_ 1783533245476896768
author Caocci, Giovanni
La Nasa, Giorgio
author_facet Caocci, Giovanni
La Nasa, Giorgio
author_sort Caocci, Giovanni
collection PubMed
description
format Online
Article
Text
id pubmed-7220809
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72208092020-05-14 Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? Caocci, Giovanni La Nasa, Giorgio Ann Hematol Letter to the Editor Springer Berlin Heidelberg 2020-05-14 2020 /pmc/articles/PMC7220809/ /pubmed/32405693 http://dx.doi.org/10.1007/s00277-020-04067-6 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Letter to the Editor
Caocci, Giovanni
La Nasa, Giorgio
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
title Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
title_full Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
title_fullStr Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
title_full_unstemmed Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
title_short Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
title_sort could ruxolitinib be effective in patients with covid-19 infection at risk of acute respiratory distress syndrome (ards)?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220809/
https://www.ncbi.nlm.nih.gov/pubmed/32405693
http://dx.doi.org/10.1007/s00277-020-04067-6
work_keys_str_mv AT caoccigiovanni couldruxolitinibbeeffectiveinpatientswithcovid19infectionatriskofacuterespiratorydistresssyndromeards
AT lanasagiorgio couldruxolitinibbeeffectiveinpatientswithcovid19infectionatriskofacuterespiratorydistresssyndromeards

Ejemplares similares